TY - JOUR AU - Ross, J. S. AU - Fletcher, J. A. PY - 1998 DA - 1998// TI - The HER-2/neuoncogene in breast cancer: prognostic factor, predictive factor, and target for therapy JO - Oncologist VL - 3 ID - Ross1998 ER - TY - JOUR AU - Slamon, D. J. AU - Clark, G. M. AU - Wong, S. G. AU - Levin, W. J. AU - Ullrich, A. AU - McGuire, W. L. PY - 1987 DA - 1987// TI - Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neuoncogene JO - Science VL - 235 UR - https://doi.org/10.1126/science.3798106 DO - 10.1126/science.3798106 ID - Slamon1987 ER - TY - JOUR AU - Slamon, D. J. AU - Godolphin, W. AU - Jones, L. A. AU - Holt, J. A. AU - Wong, S. G. AU - Keith, D. E. AU - Levin, W. J. AU - Stuart, S. G. AU - Udove, J. AU - Ullrich, A. PY - 1989 DA - 1989// TI - Studies of the HER-2/neuproto-oncogene in human breast and ovarian cancer JO - Science VL - 244 UR - https://doi.org/10.1126/science.2470152 DO - 10.1126/science.2470152 ID - Slamon1989 ER - TY - JOUR AU - Cobleigh, M. A. AU - Vogel, C. L. AU - Tripathy, D. AU - Robert, N. J. AU - Scholl, S. AU - Fehrenbacher, L. AU - Wolter, J. M. AU - Paton, V. AU - Shak, S. AU - Lieberman, G. AU - Slamon, D. J. PY - 1999 DA - 1999// TI - Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease JO - J Clin Oncol VL - 17 ID - Cobleigh1999 ER - TY - JOUR AU - Vogel, C. L. AU - Cobleigh, M. A. AU - Tripathy, D. AU - Gutheil, J. C. AU - Harris, L. N. AU - Fehrenbacher, L. AU - Slamon, D. J. AU - Murphy, M. AU - Novotny, W. F. AU - Burchmore, M. PY - 2002 DA - 2002// TI - Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.20.3.719 DO - 10.1200/JCO.20.3.719 ID - Vogel2002 ER - TY - JOUR AU - Marty, M. AU - Cognetti, F. AU - Maraninchi, D. AU - Snyder, R. AU - Mauriac, L. AU - Tubiana-Hulin, M. AU - Chan, S. AU - Grimes, D. AU - Antón, A. AU - Lluch, A. PY - 2005 DA - 2005// TI - Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.04.173 DO - 10.1200/JCO.2005.04.173 ID - Marty2005 ER - TY - JOUR AU - Piccart-Gebhart, M. J. AU - Procter, M. AU - Leyland-Jones, B. AU - Goldhirsch, A. AU - Untch, M. AU - Smith, I. AU - Gianni, L. AU - Baselga, J. AU - Bell, R. AU - Jackisch, C. PY - 2005 DA - 2005// TI - Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMoa052306 DO - 10.1056/NEJMoa052306 ID - Piccart-Gebhart2005 ER - TY - JOUR AU - Press, M. F. AU - Slamon, D. J. AU - Flom, K. J. AU - Park, J. AU - Zhou, J. -. Y. AU - Bernstein, L. PY - 2002 DA - 2002// TI - Evaluation of HER-2/neugene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens JO - J Clin Oncol VL - 20 ID - Press2002 ER - TY - JOUR AU - Zarbo, R. J. AU - Hammond, M. E. PY - 2003 DA - 2003// TI - Conference summary, strategic science symposium. Her-2/neu testing of breast cancer patients in clinical practice JO - Arch Pathol Lab Med VL - 127 ID - Zarbo2003 ER - TY - JOUR AU - Ellis, I. O. AU - Bartlett, J. AU - Dowsett, M. AU - Humphreys, S. AU - Jasani, B. AU - Miller, K. AU - Pinder, S. E. AU - Rhodes, A. AU - Walker, R. PY - 2004 DA - 2004// TI - Best Practice No 176. Updated recommendations for HER2 testing in the UK JO - J Clin Pathol VL - 57 UR - https://doi.org/10.1136/jcp.2003.007724 DO - 10.1136/jcp.2003.007724 ID - Ellis2004 ER - TY - JOUR AU - Vincent-Salomon, A. AU - MacGrogan, G. AU - Couturier, J. AU - Arnould, L. AU - Denoux, Y. AU - Fiche, M. AU - Jacquemier, J. AU - Mathieu, M. C. AU - Penault-Llorca, F. AU - Rigaud, C. PY - 2003 DA - 2003// TI - Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study JO - Histopathology VL - 42 UR - https://doi.org/10.1046/j.1365-2559.2003.01598.x DO - 10.1046/j.1365-2559.2003.01598.x ID - Vincent-Salomon2003 ER - TY - JOUR AU - Hammock, L. AU - Lewis, M. AU - Phillips, C. AU - Cohen, C. PY - 2003 DA - 2003// TI - Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situhybridization JO - Hum Pathol VL - 34 UR - https://doi.org/10.1053/S0046-8177(03)00409-X DO - 10.1053/S0046-8177(03)00409-X ID - Hammock2003 ER - TY - JOUR AU - Roche, P. C. AU - Ingle, J. N. PY - 1999 DA - 1999// TI - Increased HER2 with U.S. Food and Drug Administration-approved antibody [letter] JO - J Clin Oncol VL - 17 ID - Roche1999 ER - TY - JOUR AU - Tubbs, R. R. AU - Pettay, J. D. AU - Roche, P. C. AU - Stoler, M. H. AU - Jenkins, R. B. AU - Grogan, T. M. PY - 2001 DA - 2001// TI - Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message JO - J Clin Oncol VL - 19 ID - Tubbs2001 ER - TY - JOUR AU - Arnould, L. AU - Denoux, Y. AU - MacGrogan, G. AU - Penault-Llorca, F. AU - Fiche, M. AU - Treilleux, I. AU - Mathieu, M. C. AU - Vincent-Salomon, A. AU - Vilain, M. O. AU - Couturier, J. PY - 2003 DA - 2003// TI - Agreement between chromogenic in situhybridisation (CISH) and FISH in the determination of HER2 status in breast cancer JO - Br J Cancer VL - 88 UR - https://doi.org/10.1038/sj.bjc.6600943 DO - 10.1038/sj.bjc.6600943 ID - Arnould2003 ER - TY - JOUR AU - Gupta, D. AU - Middleton, L. P. AU - Whitaker, M. J. AU - Abrams, J. PY - 2003 DA - 2003// TI - Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neuoncogene in breast cancer JO - Am J Clin Pathol VL - 119 UR - https://doi.org/10.1309/P40P2EAD42PUKDMG DO - 10.1309/P40P2EAD42PUKDMG ID - Gupta2003 ER - TY - JOUR AU - Isola, J. AU - Tanner, M. AU - Forsyth, A. AU - Cooke, T. G. AU - Watters, A. D. AU - Bartlett, J. M. PY - 2004 DA - 2004// TI - Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situhybridization JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-0428-03 DO - 10.1158/1078-0432.CCR-0428-03 ID - Isola2004 ER - TY - JOUR AU - Tanner, M. AU - Gancberg, D. AU - Di Leo, A. AU - Larsimont, D. AU - Rouas, G. AU - Piccart, M. J. AU - Isola, J. PY - 2000 DA - 2000// TI - Chromogenic in situ hybridization. A practical alternative for fluorescence in situhybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples JO - Am J Pathol VL - 157 UR - https://doi.org/10.1016/S0002-9440(10)64785-2 DO - 10.1016/S0002-9440(10)64785-2 ID - Tanner2000 ER - TY - JOUR AU - Zhao, J. AU - Wu, R. AU - Au, A. AU - Marquez, A. AU - Yu, Y. AU - Shi, Z. PY - 2002 DA - 2002// TI - Determination of HER2 gene amplification by chromogenic in situhybridization (CISH) in archival breast carcinoma JO - Mod Pathol VL - 15 UR - https://doi.org/10.1038/modpathol.3880582 DO - 10.1038/modpathol.3880582 ID - Zhao2002 ER - TY - JOUR AU - Dal Lago, L. AU - Durbecq, V. AU - Desmedt, C. AU - Salgado, R. AU - Verjat, T. AU - Lespagnard, L. AU - Ma, Y. AU - Veys, I. AU - Di Leo, A. AU - Sotiriou, C. PY - 2006 DA - 2006// TI - Correction for chromosome-17 is critical for the determination of true Her-2/neugene amplification status in breast cancer JO - Mol Cancer Ther VL - 5 UR - https://doi.org/10.1158/1535-7163.MCT-06-0129 DO - 10.1158/1535-7163.MCT-06-0129 ID - Dal Lago2006 ER - TY - JOUR AU - Wolff, A. C. AU - Hammond, M. E. H. AU - Schwartz, J. N. AU - Hagerty, K. L. AU - Allred, D. C. AU - Cote, R. J. AU - Dowsett, M. AU - Fitzgibbons, P. L. AU - Hanna, W. M. AU - Langer, A. PY - 2007 DA - 2007// TI - American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.2775 DO - 10.1200/JCO.2006.09.2775 ID - Wolff2007 ER - TY - CHAP AU - van de Vijver, M. AU - Bilous, M. AU - Hanna, W. AU - Hofmann, M. AU - Kristel, P. AU - Penault-Llorca, F. AU - Rüschoff, J. PY - 2007 DA - 2007// TI - Chromogenic in-situhybridisation for the assessment of HER2 status in breast cancer: an international validation ring study BT - Breast Cancer Res ID - van de Vijver2007 ER -